Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
Product Sales Excluding Veklury Increased Year-Over-Year by 8% for Full Year 2022 Biktarvy Sales Increased Year-Over-Year by 20% for Full…
Pharmaceuticals, Biotechnology and Life Sciences
Product Sales Excluding Veklury Increased Year-Over-Year by 8% for Full Year 2022 Biktarvy Sales Increased Year-Over-Year by 20% for Full…
Massive Bio, which uses artificial intelligence to match cancer patients to clinical trials, was named to the New York City…
BOONE, N.C.–(BUSINESS WIRE)–Pneuma Respiratory, a med-tech pharmaceutical company focused on the advancement of inhaled respiratory therapeutics, has created a new…
LACHEN, Switzerland–(BUSINESS WIRE)–Octapharma AG today announced that European medical authorities have approved the lyophilised presentation of the well-established octaplasLG® –…
SWITCH-1 Phase IIb, was a multicenter, multicounty, double-blind, placebo-controlled, dose-range finding study with an adaptive randomization design evaluating elinzanetant in…
SABI Mind receives approval from the Health Research Ethics Board of Alberta (HREBA) to launch study sponsored by Clairvoyant Therapeutics…
STONY BROOK, N.Y.–(BUSINESS WIRE)–$APDN #LinearDNA—Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain…
Acquisition eliminates all future royalty payment obligations for PH94B and PH10 and expands Vistagen’s pipeline SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$VTGN…
Proprietary artificial intelligence capabilities and access to deep clinical notes enables OM1 to extract and analyze difficult-to-obtain insights about treatment…
– Topline results expected in 2024 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the…